G.P. is director and chief scientific officer of Drug Target ID, Ltd., but activities at this company do not constitute competing interests regarding this paper. C.E.T. has research contracts with Acumen, ADx Neurosciences, AC‐Immune, Alamar, Aribio, Axon Neurosciences, Beckman‐Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, and Vivoryon. She is Editor‐in‐Chief of Alzheimer's Research & Therapy , and serves on editorial boards of Medidact Neurologie /Springer, and Neurology: Neuroimmunology & Neuroinflammation . She had consultancy/speaker contracts with Eli Lilly, Merck, Novo Nordisk, Olink, and Roche. B.F. has received educational speaking fees and travel support from Medice. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). S.L. currently works at Johnson & Johnson. F.F.A. and S.J.M. have been consultants/speakers for NovoNordisk. P.J.V. received grants from Innovative Medicine Initiative, ZonMw, and Biogen. All other authors have nothing to disclose. Author disclosures are available in the Supporting Information.
PubMed
